Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 11/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 10/20 | 0.48 |
| ▸ | PGR | P06401 | 9/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1635036 | 0.86 | PARP1 (0.48) | NR3C1NR3C2PGRPTGS1PTGS2 | |
| SCHEMBL1634226 | 0.86 | NR3C1 (0.48) | NR3C1NR3C2PGRPTGS1PTGS2 | |
| SCHEMBL1633800 | 0.85 | NR3C1 (0.48) | NR3C1NR3C2PGRPTGS1PTGS2 | |
| SCHEMBL5776633 | 0.84 | NR3C1 (0.43) | NR3C1NR3C2PGRPTGS1PTGS2 | |
| SCHEMBL4154304 | 0.83 | PTGS1 (0.38) | NR3C1NR3C2PGRPTGS1PTGS2 | |
| SCHEMBL5523272 | 0.82 | NR3C1 (0.51) | NR3C1NR3C2PGRPTGS1PTGS2 | |
| SCHEMBL5777309 | 0.82 | NR3C1 (0.52) | NR3C1NR3C2PGRPTGS1PTGS2 | |
| SCHEMBL5780728 | 0.81 | NR3C1 (0.43) | NR3C1NR3C2PGRPTGS1PTGS2 | |
| SCHEMBL1493954 | 0.80 | NR3C1 (0.52) | NR3C1NR3C2PGRPTGS1PTGS2 | |
| SCHEMBL4165352 | 0.79 | NR3C1 (0.43) | NR3C1NR3C2PGRPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8268859-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268859-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268859-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| EP-2300472-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2012-01-18 | — | — | EP | disclosed |
| EP-2300472-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2012-01-18 | — | — | EP | disclosed |
| EP-2300472-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2011-03-30 | — | — | EP | disclosed |
| US-20090325988-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009149139-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009149139-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | WO | disclosed |
| US-7256300-B2 | Stereoselective synthesis of certain trifluoromethyl-substituted alcohols | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256300-B2 | Stereoselective synthesis of certain trifluoromethyl-substituted alcohols | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256300-B2 | Stereoselective synthesis of certain trifluoromethyl-substituted alcohols | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1673088-A1 | 1,1,1- TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO¬2,3-C|PYRIDIN-2-YLMETHYL)PENTAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS GLUCOCORTICOID LIGANDS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DIABETES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005100335-A1 | STEREOSELECTIVE SYNTHESIS OF CERTAIN TRIFLUOROMETHYL-SUBSTITUTED OXIRANES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050234250-A1 | Stereoselective synthesis of certain trifluoromethyl-substituted alcohols | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005030213-A1 | 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885NR3C2 2/4885PGR 95/4885 |
| US-20090325988-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885NR3C2 2/4885PGR 187/4885 |
| US-20050234250-A1 | Stereoselective synthesis of certain trifluoromethyl-substituted alcohols | NR3C1, NR3C2, MC2R | NR3C1 1/4885NR3C2 2/4885PGR 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.